Allogene Therapeutics announced interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cema-cel in first-line consolidation for large B-cell lymphoma, showing 58.3% of patients in the treatment arm achieved MRD negativity compared to 16.7% in the observation arm.
Key takeaways
Interim analysis of 24 patients showed 58.3% MRD negativity in cema-cel arm vs 16.7% in observation arm, a 41.6% absolute difference.
Cema-cel demonstrated favorable safety profile with no CRS, ICANS, or GvHD events and 10 of 12 patients managed outpatient post-infusion.
The ALPHA3 trial is enrolling across 60+ sites targeting 220 patients, with study completion expected by end of 2027 and primary analysis in mid-2028.
If positive, trial results could support a Biologics License Application submission for cema-cel as a novel treatment strategy for high-risk LBCL patients.